Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 2Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 4Small Cell Lung Carcinoma 2Neoplasms 2Thoracic Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Lung Diseases 1Extensive Stage Small Cell Lung Cancer 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × ceralasertib × Thoracic × Clear all
NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡